YM BioSciences, Inc. (USA) (NYSEMKT:YMI.DL)

CAPS Rating: No stars

A biopharmaceutical company engaged in the development of products for the treatment of patients with cancer.


Player Avatar zzlangerhans (99.85) Submitted: 12/18/2010 3:36:45 AM : Underperform Start Price: $1.92 YMI.DL Score: +6.30

For those who missed the hint in my last red thumb, I was predicting the hefty dilutive financing that swatted down the share price a couple of weeks ago. Now the share price is back over 1.9 just days after the company sold 40M in stock at 1.6. Hmmm.

There's recently been some good news and bad news on YMI. The good news is encouraging preliminary phase II data for JAK inhibitor CYT387 in myelofibrosis, with a 62% overall response rate. It's always nice to have a follow-up act when your headliner seems to be treading water. YMI claims that their partners' nimo trials are progressing on schedule while their in-house phase II studies are lagging in recruitment and may get tabled. Hmmm.

A prediction of phase II data for nimo in pediatric glioma before the end of 2010 is buried deep in the company's most recent PR, which makes me dubious that the program is likely to progress further. Hmmm.

YMI might be a good buy at some point in the future as CYT387 matures and we get a better impression of whether this is a truly promising candidate, or more smoke and mirrors. For now, nimo is an excessive weight on the pipeline.

Report this Post 3 Replies
Member Avatar doctorblood (< 20) Submitted: 12/21/2010 9:50:36 PM
Recs: 1

Look to the anemic, my friend. For the drug that helps those will be the JaK inhibitor that wins the day...

Member Avatar hiddenflem (78.73) Submitted: 1/26/2011 2:14:29 PM
Recs: 0

Yes, what about anemia zzlangerhans? It's a huge indication...I guess your short is counting on the fact that the previous data will not be supported at ASCO?

Featured Broker Partners